❖ It is evaluating 20 leading pharmaceutical companies on their efforts to expand access to their products in low- and middle-income countries (LMIC). 

❖ Overall industry performance has declined since the 2022 Index.

❖ 61 per cent of the products assessed still lacking access strategies for low-income countries, compared with 65 per cent in the 2022 Index.

❖ Only 43 per cent of clinical trials take place in the 113 LMICs.